



HMDS, Bexley Wing, St. James’s University Hospital, Leeds, LS9 7TF. Tel 0113 2067851

Third primary dose of COVID-19 vaccine

Some individuals who are immunosuppressed due to underlying health conditions or medical treatment may not mount a full immune response to primary COVID-19 vaccination. The Joint Committee on Vaccination and Immunisation (JCVI) recommends that a third dose is given for individuals aged 12 and over with immunosuppression (see the Green Book Chapter 14a).

This includes individuals under follow up for a chronic lymphoproliferative disorder including haematological malignancies such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom’s macroglobulinemia and other plasma cell dyscrasias (Note: this list is not exhaustive).

The table below lists diagnoses that are monitored through the Outreach service and meet the JCVI criteria. The diagnostic category is shown in large bold letters in the top right box on the Outreach report. If you have one of the diagnoses listed below, please arrange a third primary dose of the COVID vaccine through the NHS website or contact your GP. A copy of this page and your most recent Outreach report should be sufficient to arrange the vaccination but please let us know if you need additional information.

The third dose is being advised as a precautionary measure to increase your immunity level and provide a better vaccine response, based on studies and experience with other vaccines. It is part of your primary course of vaccination and is separate to a booster vaccination, which you will likely become eligible for in six months’ time, pending further advice.

Diagnostic category	ICDO3 CODE
B-cell chronic lymphocytic leukaemia (B-cell CLL)	9823/3
B-cell CLL - minimal residual disease present	9823/3
B-cell CLL post-treatment monitoring	9823/3
B-cell LPD NOS	9823/3
CD5+ LPD - intermediate phenotype	9823/3
CD5+/CD23- LPD NOS	9823/3
CD5-negative B-cell LPD NOS	9591/3
Chronic myeloid leukaemia - major molecular response	9875/3
Chronic myeloid leukaemia - outreach monitoring	9875/3
Chronic myeloid leukaemia - treated	9875/3
Hairy cell leukaemia	9940/3
Hairy cell leukaemia - variant	9940/3
HCL - residual disease detected	9940/3
IgM MGUS	9761/1
Monoclonal B-cell lymphocytosis (CLL phenotype)	9823/3
Monoclonal gammopathy of undetermined significance (MGUS)	9765/1
MYD88 mutated B-cell lymphoproliferative disorder	9689/3
Systemic marginal zone lymphoma	9689/3
T cell LGL leukaemia	9831/3
T-cell or NK cell large granular lymphocytosis	9831/3
WM post-treatment monitoring	9689/3